EPA chemical testing is becoming a more demanding documentation issue for manufacturers, importers, and downstream users that rely on TSCA review pathways. The main shift is not a single procedural change. It is a combined movement toward fuller review for higher-concern new chemicals, closer tracking of health and safety information, and more formal use of non-animal methods where EPA accepts the evidence.

The strongest confirmed change in the research record is EPA’s December 2024 final amendment under TSCA. EPA stated that new PFAS and other persistent, bioaccumulative, and toxic chemicals are no longer eligible for low volume or low release and exposure exemptions, meaning they must undergo full safety review before manufacture under the amended new chemicals regulations EPA new chemicals update. For industry, that changes planning assumptions around early production, pilot commercialization, and the evidence expected before a substance moves into commerce.

EPA chemical testing Is Moving Toward More Review

Why EPA chemical testing Files Need Earlier Scope Checks

As of September 1, 2026, the research notes identify 421 active TSCA new-chemical cases under EPA review. Those cases included premanufacture notices, significant new use notices, and microbial commercial activity notices. The same research record reported about 218 cases in risk assessment, 49 in risk management, 81 awaiting more information from submitters, and 73 awaiting a consent order signature.

Those figures should be read as a dated snapshot, not as a permanent caseload. Even with that caution, they show why companies cannot treat submission as the last major compliance step. A file may move into risk assessment, pause for missing information, or require a consent order before commercial activity proceeds under defined conditions.

EPA chemical testing expectations therefore affect more than toxicology teams. Product development, purchasing, legal, regulatory affairs, EHS, and customer-facing technical service groups may all need access to the same controlled identity, use, exposure, and data records. If those records are assembled only after an EPA information request, the review process can expose gaps that were already present during product planning.

Exemptions Are Narrower For Certain New Chemicals

The research notes state that EPA’s TSCA New Chemicals Program receives about 500 notices per fiscal year, and that more than half are exemption applications such as low volume, low release and exposure, or test marketing exemptions. Those exemption categories can have shorter review periods than full reviews, but the December 2024 rule change narrowed their use for new PFAS and other PBT chemicals.

That does not mean every chemical is subject to the same evidence burden. It does mean exemption eligibility should be documented as a regulatory conclusion, not assumed from production volume or intended release profile alone. For PFAS and PBT candidates, a company should be prepared for a full review pathway and should avoid building launch timelines around an exemption that is no longer available for those categories.

Alternative Methods Are Gaining Formal Attention

EPA chemical testing And NAM Evidence

In January 2026, EPA committed through an administrator memo to eliminate testing on mammals by 2035. The research notes describe a shift toward New Approach Methodologies, or NAMs, including human tissue models and computational approaches. On August 27, 2026, EPA announced two scientific developments intended to reduce reliance on new animal tests: a human airway tissue model for assessing lung irritation from surfactants and use of the GHS mixture formula to predict oral toxicity in pesticide mixtures.

These developments matter, but they should not be interpreted as a blanket replacement for all legacy testing needs. NAM evidence still has to match the endpoint, chemical category, exposure question, and regulatory context. A computational estimate may support a screening or grouping rationale, while a tissue model may support a specific irritation question. Neither automatically resolves every hazard, exposure, persistence, or risk-management issue in a TSCA file.

For companies preparing EPA chemical testing submissions, the practical question is whether the alternative method is accepted for the specific decision being made. A related discussion of non-animal testing documentation explains why scope statements and documented limits remain necessary even when a non-animal approach is scientifically useful.

What Industry Should Not Assume

The movement toward NAMs can reduce some testing burden and may improve relevance for certain endpoints, but the research record does not support a claim that animal testing has already ended. The 2035 target is prospective, and individual methods still need defined use cases. Companies should therefore preserve the reasoning behind method selection, the endpoint addressed, the uncertainty left unresolved, and any EPA feedback received.

• Record the regulatory purpose of each study or model result.
• Separate accepted endpoint evidence from exploratory screening information.
• Track whether a method supports hazard identification, exposure estimation, or risk characterization.
• Retain correspondence and assumptions used in EPA submissions.

Data Reporting Pressure Is Changing Documentation

Health And Safety Study Records Need Ownership

In May 2026, EPA extended the deadline to May 21, 2027 for reporting unpublished health and safety studies for 16 chemicals under TSCA section 8(d). The research notes also state that EPA was reconsidering the December 13, 2024 TSCA 8(d) rule in response to legal challenge, with potential changes involving exemptions, reporting thresholds, and look-back periods.

Because that rule was under reconsideration by September 19, 2026, companies should avoid treating every proposed adjustment as final. The safer documentation practice is to identify the affected substances, locate unpublished health and safety studies, assign record owners, and preserve decision logs showing why a study was considered reportable or outside scope at the time of review.

Inventory Status Is A Separate Evidence Question

The research notes state that the non-confidential TSCA Inventory was last updated in July 2026 and listed 42,698 active chemicals in U.S. commerce and 44,043 inactive chemicals. That inventory status is useful, but it is not a substitute for a complete new-chemical, significant-new-use, or reporting analysis.

A substance may appear in procurement history, supplier records, research batches, customer samples, or legacy formulations. None of those facts alone proves the current regulatory path. Industry standards are moving toward controlled evidence files that connect substance identity, inventory status, use, volume, exposure assumptions, test data, and claim status for confidential business information where applicable.

Risk Management Decisions Affect Operations

The research notes report that in May 2026 EPA finalized a regulation restricting 15 industrial and commercial uses of 1,2-dichloroethane after finding unreasonable risks to workers in 15 of 20 evaluated use scenarios, driven by inhalation and dermal exposure. That example shows how chemical testing and risk evaluation can move from technical assessment into workplace controls, use restrictions, and customer communication.

For manufacturers, the compliance impact is often procedural. A risk determination may require review of exposure controls, technical data sheets, SDS alignment, purchasing restrictions, downstream use statements, and change notices. The evidence file should show not only what the company knows about the chemical, but how that knowledge is reflected in operational decisions.

Cross-functional governance also matters where chemical management intersects with energy, utilities, and site performance records. Companies comparing documentation structures across environmental programs may find useful guidance and compliance context through resources provided by the Illinois Energy website, especially when ensuring regulatory records are consistent across various departments within a facility.

EPA chemical testing Requires Evidence Discipline

EPA chemical testing has become less tolerant of informal assumptions. The December 2024 new-chemicals amendment removed exemption pathways for new PFAS and other PBT chemicals. The September 1, 2026 caseload snapshot showed many cases in assessment, risk management, waiting for submitter information, or awaiting consent order signatures. The 2026 alternative-method announcements showed direction toward reduced mammal testing, but not a complete replacement of all existing evidence needs.

The practical industry standard is therefore an evidence discipline standard. A company should be able to explain what it submitted, why a method was selected, which uses were covered, which uncertainties remained, what EPA status applied on a given date, and how any conditions were communicated to operations and customers.

That approach does not guarantee a faster review or a favorable determination. It does reduce avoidable ambiguity. In a TSCA environment where exemptions, health and safety reporting, inventory status, and risk-management outcomes are all active compliance variables, the strongest position is a documented one.